Feline hyperthyroidism can be treated by thyroidectomy, antithyroid drugs, or radioactive iodine-131 (131I). The aim of this retrospective study was to evaluate the treatment of 83 hyperthyroid cats with 131I The dosage of 131I ranged from 4 to 6 milliCurie (mCi). Blood samples for determination of plasma concentrations of total thyroxine (TT4), urea, and creatinine were collected before, ten days after, and several months after treatment. In addition, arterial blood pressure was measured before and ten days after treatment. The median plasma TT4 concentration ten days after 131I treatment (27 nmol/L, 64 cats) was significantly lower than that before treatment (123 nmol/L). The median plasma TT4 concentration several months after 131I treatment was 22,5 nmol/L (40 cats). Ten days and several months after 131I treatment, plasma TT4 concentration had decreased below the upper limit of the reference range in 64 (77%) and 72 cats (87%), respectively. In four cats the plasma TT4 concentration had decreased below the lower limit of the reference range, but only two cats had symptoms of hypothyroidism. Plasma urea and creatinine concentrations were not increased ten days after 131I treatment, but the median plasma creatinine concentration was significantly higher several months after treatment when compared with before 131I treatment. Before treatment in 28 cats a high arterial blood pressure (> 180 mmHg) was measured, whereas after treatment in 25 cats a high arterial blood pressure was measured. The results of this study indicate that 131I treatment is an effective therapy in most cats with hyperthyroidism.
Download full-text PDF |
Source |
---|
Curr Radiopharm
January 2025
Apollonia" University of Iasi, Faculty of Dental Medicine, 11 Pacurari Str., 700511, Iasi, Romania.
Background: In the context of modern oncology, radiogenic elements have emerged as pivotal tools for targeted cancer therapies. Elements like Iodine-131 and Yttrium-90 offer unique radiological properties that allow precise treatment delivery. This article explores their growing importance and potential in reshaping the landscape of cancer therapy.
View Article and Find Full Text PDFEndocr J
January 2025
Department of Surgery, Ito Hospital, Tokyo 150-8308, Japan.
We investigated the association between a 500 MBq dose of radioactive iodine treatment (RAIT) and both thyroid nodule volume and thyroid function in patients with a single autonomous functioning thyroid nodule (AFTN). We retrospectively studied 201 patients with an AFTN who received RAIT at a dose of 500 MBq and were followed up for more than 2 years. Thyroid function at diagnosis, thyroid antibody positivity, treatment with antithyroid drugs before RAIT, cystic components of the nodule, and I uptake outside the nodule were assessed.
View Article and Find Full Text PDFInt J Nanomedicine
January 2025
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China.
Purpose: None of the antibody-drug conjugates (ADCs) targeting Claudin 18.2 (CLDN18.2) have received approval from regulatory authorities due to their limited clinical benefits.
View Article and Find Full Text PDFNucl Med Commun
January 2025
Department of Nuclear Medicine, First Hospital of Shanxi Medical University.
Objectives: To investigate the effects of selenium on functional and histopathological changes and mRNA expression levels of insulin-like growth factors 1 and 2 (IGF-1 and -2) and aquaporins 4 and 5 (AQP-4 and -5) in 131I-induced damaged rat parotid glands.
Methods: Rats were divided into three groups: iodotherapy-with-selenium, iodotherapy-only, and control. Rats in the iodotherapy-with-selenium group were intragastrically administered 131I on the first day and selenomethionine through drinking water.
Sci Rep
January 2025
Department of Nuclear Medicine, Zhejiang Cancer Hospital, Hangzhou, 310022, Zhejiang, China.
This study aimed to establish and validate prognostic nomogram models for patients who underwent I therapy for thyroid cancer with distant metastases. The cohort was divided into training (70%) and validation (30%) sets for nomogram development. Univariate and multivariate Cox regression analyses were used to identify independent predictors for overall survival (OS) and progression-free survival (PFS).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!